Head-to-head
Semaglutide vs MOTS-c
A field-by-field comparison of Semaglutide and MOTS-c drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. Both are indexed as metabolic compounds, so the useful question is how they differ within that category.
Semaglutide vs MOTS-c at a glance
| Attribute | Semaglutide | MOTS-c |
|---|---|---|
| Category | Metabolic | Metabolic |
| Evidence grade | Strong | Emerging |
| Also known as | Ozempic, Wegovy | Mitochondrial open reading frame of the 12S rRNA-c, MT-RNR1-encoded peptide |
| Chain | GLP-1 analogue, 94% homology to human GLP-1 | 16 amino acid mitochondrial-derived peptide |
| Mechanism | Mimics GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and act on hypothalamic appetite centres. Fatty-acid acylation extends its half-life to once-weekly dosing. | Encoded by mitochondrial 12S rRNA, MOTS-c translocates to the nucleus and activates the folate/AMPK axis. This improves cellular glucose uptake, increases fatty-acid oxidation and promotes metabolic flexibility under nutrient stress. |
| Reported benefits | ~15% mean body-weight reduction over 68 weeks in STEP-1 · Improved HbA1c and cardiovascular outcomes · Marked reduction in appetite and food noise | Improved insulin sensitivity and glucose disposal in rodent models · Enhanced fat oxidation and reduced fat accumulation · Exercise-mimetic effects on metabolism and physical capacity · Potential protection against diet-induced metabolic dysfunction |
| Reported side effects | Nausea and vomiting · Constipation or diarrhoea · Gallbladder issues · Contraindicated with medullary thyroid carcinoma history | Limited human safety data · Injection-site irritation · Possible hypoglycaemia in susceptible individuals |
| Half-life | About 7 days | Estimated minutes to a few hours |
| Administration | Once-weekly subcutaneous injection (oral tablet also approved) | Subcutaneous injection; oral capsules are marketed but less validated |
| Dosing overview | Label titration from 0.25 mg weekly up to 2.4 mg over 16+ weeks | Commonly cited at 5–10 mg daily, often for 4–12 week cycles |
| Storage | Refrigerate 2–8 °C; in-use pens may be kept at room temperature per label | Lyophilised powder refrigerated; reconstituted vials 2–8 °C and used within ~30 days |
| Legal status | FDA-approved and prescription-only. | Research chemical; not approved as a drug. |
Key differences between Semaglutide and MOTS-c
Both are metabolic compounds
Semaglutide and MOTS-c are both indexed under metabolic, so they compete for the same use case rather than complementing each other. Semaglutide: "A long-acting GLP-1 receptor agonist with the strongest clinical weight-loss evidence of any peptide on the market." MOTS-c: "A mitochondrial-encoded peptide that acts as a metabolic regulator, studied for insulin sensitivity, fat oxidation and exercise-mimetic effects."
Mechanism of action
Semaglutide: Mimics GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and act on hypothalamic appetite centres. Fatty-acid acylation extends its half-life to once-weekly dosing. MOTS-c: Encoded by mitochondrial 12S rRNA, MOTS-c translocates to the nucleus and activates the folate/AMPK axis. This improves cellular glucose uptake, increases fatty-acid oxidation and promotes metabolic flexibility under nutrient stress.
Evidence quality is not equal
Semaglutide carries a Strong evidence grade and MOTS-c a Emerging grade on this index. The grade describes the quality of published human data, not how well a compound works — Semaglutide has the better-documented record of the two, and claims made about MOTS-c rest on thinner human evidence.
Half-life and dosing frequency
Semaglutide is listed at about 7 days; MOTS-c at estimated minutes to a few hours. That difference is what drives the reported schedules: Label titration from 0.25 mg weekly up to 2.4 mg over 16+ weeks versus Commonly cited at 5–10 mg daily, often for 4–12 week cycles
Route of administration
Semaglutide is administered by once-weekly subcutaneous injection (oral tablet also approved). MOTS-c is administered by subcutaneous injection; oral capsules are marketed but less validated.
Legal and regulatory status differs
Semaglutide: FDA-approved and prescription-only. MOTS-c: Research chemical; not approved as a drug. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.
Handling and storage
Semaglutide is stored refrigerate 2–8 °c; in-use pens may be kept at room temperature per label. MOTS-c is stored lyophilised powder refrigerated; reconstituted vials 2–8 °c and used within ~30 days.
What Semaglutide and MOTS-c have in common
- Category: both listed as Metabolic
Each compound in brief
Semaglutide
Metabolic · Strong evidence
A long-acting GLP-1 receptor agonist with the strongest clinical weight-loss evidence of any peptide on the market.
Considerations: Muscle loss can account for a meaningful share of weight lost — resistance training and protein intake matter · GI side effects are dose-dependent; titrate slowly · Weight regain is common after stopping
MOTS-c
Metabolic · Emerging evidence
A mitochondrial-encoded peptide that acts as a metabolic regulator, studied for insulin sensitivity, fat oxidation and exercise-mimetic effects.
Considerations: Most evidence is preclinical; human trials are small and early-phase · Short half-life may require daily or twice-daily dosing · Bioavailability of oral forms is uncertain compared with injection
Related comparisons and reading
Every figure on this page is reproduced from the compound profiles in this database and reflects published literature and commonly reported protocols. It is educational information, not medical advice, and not a recommendation to use either compound. See the medical disclaimer.